PMID: 8614120May 1, 1996Paper

Use of terfenadine and contraindicated drugs

JAMA : the Journal of the American Medical Association
D Thompson, G Oster

Abstract

To assess changes in concurrent use of products containing terfenadine and contraindicated macrolide antibiotics (erythromycin, clarithromycin, troleandomycin) and imidazole antifungals (ketoconazole, itraconazole) following reports of serious drug-drug interactions and changes in product labeling. Retrospective review of computerized pharmacy claims. A large health insurer in New England. Health plan members with 1 or more paid pharmacy claims for products containing terfenadine between January 1990 and June 1994. Among persons with paid claims for terfenadine in any given month, percentage with a prescription for any contraindicated drug that alternatively was dispensed on the same day as ("same-day dispensing") or had therapy days that overlapped those of ("overlapping use") a prescription for terfenadine. Concurrent use of terfenadine and contraindicated drugs declined over the study period. The rate of same-day dispensing declined by 84% from an average of 2.5 per 100 persons receiving terfenadine in 1990 to 0.4 per 100 persons during the first 6 months of 1994, while the rate of overlapping use declined by 57% (from 5.4 to 2.3 per 100 persons). Most cases involved erythromycin. Despite substantial declines following repor...Continue Reading

Citations

Sep 5, 2002·British Journal of Clinical Pharmacology·Rashmi R Shah
Apr 6, 2006·The AAPS Journal·F Peter Guengerich
Nov 17, 2010·Pharmacological Reviews·Prince KannankerilDawood Darbar
Jul 12, 2002·Drugs·Peter M Haddad, Ian M Anderson
Nov 17, 2006·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Robert C Owens, Thomas D Nolin
Sep 12, 1998·Primary Care·D Weldon
Jul 1, 1997·Dermatologic Clinics·H I Katz, A K Gupta
Apr 23, 2014·Birth Defects Research. Part B, Developmental and Reproductive Toxicology·Mats F Nilsson, William S Webster
Jun 21, 2002·Journal of Cardiovascular Pharmacology and Therapeutics·Jean T BarbeyDouglas P Zipes
Sep 24, 2004·Pharmacoepidemiology and Drug Safety·Deborah ShatinDavid Graham
May 25, 2002·Journal of the American Geriatrics Society·Philip S WangJerry Avorn
Jun 19, 2003·Pharmacoepidemiology and Drug Safety·Jeff Jianfei GuoDewei She
Oct 22, 2005·Current Urology Reports·Roger Dmochowski, David R Staskin
Feb 12, 2009·European Journal of Clinical Pharmacology·Ylva BöttigerBirgit Eiermann
Jun 25, 2009·Pharmacoepidemiology and Drug Safety·Yeong-Liang LinGuei-Feng Tsai
Oct 9, 2009·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Gabriel Sanfélix-GimenoTeresa Barbera
Sep 24, 2005·Pharmacoepidemiology and Drug Safety·Nancy M Allen LaPointeRichard Platt
Jun 23, 2001·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·M Malik, A J Camm
Jun 15, 2006·Molecular Diagnosis & Therapy·Richard S JudsonMichael J Ackerman
Jun 12, 2019·Journal of Receptor and Signal Transduction Research·He-Hsiung ChengChung-Ren Jan
Nov 7, 2017·British Journal of Clinical Pharmacology·Thomas GoedeckeXavier Kurz
Jul 13, 2013·Pharmacoepidemiology and Drug Safety·Becky A BriesacherJerry H Gurwitz

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.